Constipation News and Research

Latest Constipation News and Research

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Salix Pharmaceuticals, Ltd. today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET).

22 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

CryoSTAT cold therapy for hemorrhoids

Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.

20 Apr 2010

Lactobacillus plantarum has no effect on Salmonella: University of Gothenburg

Many tourists travelling abroad go down with diarrhoea, which can be caused by Salmonella. While probiotics are often cited as the solution to various stomach problems, the probiotic, Lactobacillus plantarum has no effect on Salmonella, reveals a new thesis at the University of Gothenburg, Sweden.

20 Apr 2010

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

BioMarin Pharmaceutical Inc. announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.

19 Apr 2010

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

19 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

New clinical algorithms will give physicians a practical, efficient and cost-effective aid to diagnose the frequent gastrointestinal symptoms that patients commonly bring to their primary care doctors and gastroenterologists--symptoms of functional GI disorders that are often difficult to diagnose.

7 Apr 2010

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

5 Apr 2010

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).

2 Apr 2010

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.

19 Mar 2010

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. today announced that one abstract has been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL.

19 Mar 2010

Working rotating shifts may increase risk of developing IBS and abdominal pain

Nurses participating in shift work, especially those working rotating shifts, face a significantly increased risk of developing Irritable Bowel Syndrome (IBS) and abdominal pain compared to those working a standard day-time schedule, according to research published in the American Journal of Gastroenterology.

19 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010